A Paper-Based Multiplexed Serological Test to Monitor Immunity against SARS-COV-2 Using Machine Learning
Source abstract
Abstract
The rapid spread of SARS-CoV-2 caused the COVID-19 pandemic and accelerated vaccine development to prevent the spread of the virus and control the disease. Given the sustained high infectivity and evolution of SARS-CoV-2, there is an ongoing interest in developing COVID-19 serology tests to monitor population-level immunity. To address this critical need, we designed a paper-based multiplexed vertical flow assay (xVFA) using five structural proteins of SARS-CoV-2, detecting IgG and IgM antibodies to monitor changes in COVID-19 immunity levels. Our platform not only tracked longitudinal immunity levels but also categorized COVID-19 immunity into three groups: protected, unprotected, and infected, based on the levels of IgG and IgM antibodies. We operated two xVFAs in parallel to detect IgG and IgM antibodies using a total of 40 μL of human serum sample in <20 min per test. After the assay, images of the paper-based sensor panel were captured using a mobile phone-based custom-designed optical reader and then processed by a neural network-based serodiagnostic algorithm. The serodiagnostic algorithm was trained with 120 measurements/tests and 30 serum samples from 7 randomly selected individuals and was blindly tested with 31 serum samples from 8 different individuals, collected before vaccination as well as after vaccination or infection, achieving an accuracy of 89.5%. The competitive performance of the xVFA, along with its portability, cost-effectiveness, and rapid operation, makes it a promising computational point-of-care (POC) serology test for monitoring COVID-19 immunity, aiding in timely decisions on the administration of booster vaccines and general public health policies to protect vulnerable populations.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: SARS-CoV-2 detection and testing · SARS-CoV-2 and COVID-19 Research · Biosensors and Analytical Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. 10.1152/physiolgenomics.00089.202010.1152/physiolgenomics.00089.2020 ↗
2. Impact of Covid-19 on Global Health Goals,2021. World Health Organization. https://www.who.int/news-room/spotlight/the-impact-of-covid-19-on-global-health-goals.
3. 10.1038/s41392-023-01724-w10.1038/s41392-023-01724-w ↗
4. 10.1016/j.meegid.2022.10521710.1016/j.meegid.2022.105217 ↗
5. Ahmad, F. B.; Cisewski, J. A.; Xu, J.; Anderson, R. N. Covid-19 Mortality Update. MMWR Morbidity and Mortality Weekly Report, 2023; pp 493–496.10.15585/mmwr.mm7218a4 ↗
6. 10.1038/s41467-022-30144-710.1038/s41467-022-30144-7 ↗
7. FDA Takes Action on Updated MRNA Covid-19 Vaccines to Better Protect against Currently Circulating Variants, 2023. FDA.https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating (accessed April 7 2024).
8. 10.1038/s41598-023-31057-110.1038/s41598-023-31057-1 ↗
9. 10.1038/s41586-021-03792-w10.1038/s41586-021-03792-w ↗
10. 10.3389/fimmu.2020.61068810.3389/fimmu.2020.610688 ↗
11. 10.1016/j.intimp.2021.10809510.1016/j.intimp.2021.108095 ↗
12. 10.3389/fimmu.2022.101252610.3389/fimmu.2022.1012526 ↗
13. 10.1093/cid/ciaa31010.1093/cid/ciaa310 ↗
14. 10.1172/JCI13875910.1172/JCI138759 ↗
15. 10.1371/journal.pone.028168910.1371/journal.pone.0281689 ↗
16. 10.1016/j.cell.2021.01.00710.1016/j.cell.2021.01.007 ↗
17. 10.1128/mBio.01991-2010.1128/mBio.01991-20 ↗
18. 10.1093/infdis/jiaa27310.1093/infdis/jiaa273 ↗
19. 10.1016/j.jcv.2022.10526810.1016/j.jcv.2022.105268 ↗
20. 10.1038/s43856-021-00045-910.1038/s43856-021-00045-9 ↗
21. 10.2147/JMDH.S29071110.2147/JMDH.S290711 ↗
22. 10.3390/bios1306062310.3390/bios13060623 ↗
23. 10.1016/j.diagmicrobio.2023.11616610.1016/j.diagmicrobio.2023.116166 ↗
24. 10.1016/j.jcv.2020.10469010.1016/j.jcv.2020.104690 ↗
25. 10.1007/s00216-022-04416-610.1007/s00216-022-04416-6 ↗
26. 10.21037/jlpm-20-10510.21037/jlpm-20-105 ↗
27. 10.1002/cpmc.10010.1002/cpmc.100 ↗
28. 10.1016/j.jim.2023.11347210.1016/j.jim.2023.113472 ↗
29. 10.1021/acsnano.9b0815110.1021/acsnano.9b08151 ↗
30. 10.1002/smll.20237043110.1002/smll.202370431 ↗
31. 10.1038/s41580-021-00418-x10.1038/s41580-021-00418-x ↗
32. 10.1016/j.cmi.2021.05.00110.1016/j.cmi.2021.05.001 ↗
33. 10.2147/JIR.S43486010.2147/JIR.S434860 ↗
34. 10.1056/NEJMoa211458310.1056/NEJMoa2114583 ↗
35. 10.1016/j.vaccine.2021.10.03810.1016/j.vaccine.2021.10.038 ↗
36. 10.1126/scitranslmed.abc193110.1126/scitranslmed.abc1931 ↗
37. In Vitro Diagnostics Emergency Use Authorizations (Euas) - Serology and Other Adaptive Immune Response Tests for Sars-Cov-2, 2023. FDA.https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-emergency-use-authorizations-euas-serology-and-other-adaptive-immune-response#isft1 (accessed April 6 2024).
38. 10.5937/jomb0-3147510.5937/jomb0-31475 ↗
39. Ghosh, R.; Joung, H. A.; Goncharov, A.; Palanisamy, B.; Ngo, K.; Pejcinovic, K.; Krockenberger, N.; Horn, E. J.; Garner, O. B.; Ghazal, E.; Single-Tier Point-of-Care Serodiagnosis of Lyme Disease. bioRxiv Preprint, 2023.10.1101/2023.06.14.544508 ↗
40. 10.1038/s41467-023-40195-z10.1038/s41467-023-40195-z ↗
41. 10.1016/S0140-6736(20)32137-110.1016/S0140-6736(20)32137-1 ↗
42. 10.1039/D3SD00081H10.1039/D3SD00081H ↗
43. 10.1038/s41598-023-48581-910.1038/s41598-023-48581-9 ↗
44. 10.1016/j.bios.2020.11267910.1016/j.bios.2020.112679 ↗